Home › Multiple Myeloma › Minnesota
Multiple Myeloma clinical trials in Minnesota
30 studies for Multiple Myeloma are looking for participants at sites in Minnesota.
Cities in Minnesota
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06465316Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Mayo Clinic Health System-Mankato, Mankato
- Mayo Clinic in Rochester, Rochester
Recruiting
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06630104SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
- Mayo Clinic in Rochester, Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07850284A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Mayo Clinic Rochester, Rochester
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05201781A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07258511A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- University Of Minnesota Medical Center, Minneapolis
- Mayo Clinic, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Mayo Clinic, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07393282A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Minnesota Oncology - Minneapolis Clinic /ID# 278720, Minneapolis
- Mayo Clinic Hospital Rochester /ID# 277886, Rochester
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07095452Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Minnesota, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06297226Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT06375044Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06940297Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Minnesota Oncology - Burnsville, Burnsville
- Cambridge Medical Center, Cambridge
- Minnesota Oncology Hematology PA-Chaska, Chaska
- and 24 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Mayo Clinic - Transplant Center - Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Minneapolis
- Research Site, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05850234A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Mayo Clinic - Minnesota, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Minnesota, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06121843A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic - Rochester /ID# 251164, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Mayo Clinic, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT05137054Integrated Cancer Repository for Cancer Research
- Riverwood Healthcare Center, Aitkin
- Essentia Health-St. Joseph's Medical Center, Brainerd
- Essentia Health - Duluth Clinic, Duluth
- and 2 more
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 25, 2026 · NCT06785415Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 60 · All sexes · Updated Jun 25, 2026 · NCT03314974Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Riverwood Healthcare Center, Aitkin
- Essentia Health - Baxter Clinic, Baxter
- Sanford Joe Lueken Cancer Center, Bemidji
- and 40 more
RecruitingPhase 3
All ages · All sexes · Updated Jun 10, 2026 · NCT05561387A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT03017820Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
- University of Minnesota - Masonic Cancer Center, Minneapolis
Recruiting
Ages 18 and older · All sexes · Updated Jun 5, 2026 · NCT03858205Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Minnesota Oncology Hematology, Minneapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT05972135Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
Recruiting
Ages 65 and older · All sexes · Updated Apr 13, 2026 · NCT06145581cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Allina Health Cancer Institute, Minneapolis
- Mayo Clinic, Rochester
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881Family Study of Lymphoproliferative Disorders
- Mayo Clinic, Rochester
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 100 · All sexes · Updated Oct 14, 2025 · NCT00626496IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- University of Minnesota, Minneapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 3, 2025 · NCT06119685Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- Center for International Blood and Marrow Transplant Research, Minneapolis
RecruitingObservational study
All ages · All sexes · Updated Aug 30, 2023 · NCT03127761From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.